logo

KYMR

Kymera Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.85 / 10
Outperform

Analyst consensus is overwhelmingly bullish—66.7% Strong Buy and 33.3% Buy from three analysts—with a 75% historical win rate for recent predictions. Money flow is equally encouraging: the fund flow score of 8.07/10 indicates exceptional inflow dynamics, with Extra-large and block flows positive despite negative Small, Medium, and Large flows. This confluence of bullish analyst views and robust fund inflows supports the technical strength, but investors should remain mindful of the still-fragile fundamentals.

FundamentalSentiment(6.85)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

67%

Buy

33%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-01-28
InstitutionBarclays
Times predicted4
Historical Win Rate75.0%
What is the analyst consensus for KYMR?
  • KYMR holds a Bullish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.85/10 (Outperform).